Cidara Therapeutics Files Proxy Statement for 2025 Annual Meeting
| Field | Detail |
|---|---|
| Company | Cidara Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance, executive-compensation
Related Tickers: CDTX
TL;DR
CDTX proxy filed: vote on directors & auditors for 2025 meeting.
AI Summary
Cidara Therapeutics, Inc. filed its definitive proxy statement for the 2025 annual meeting of stockholders, to be held on June 18, 2025. The filing details executive compensation, board nominations, and other corporate governance matters for the fiscal year ending December 31, 2024. Key proposals include the election of directors and the ratification of the independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information regarding the company's leadership, compensation practices, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: medium — Proxy statements are routine filings, but the specific proposals and executive compensation details can reveal underlying company health and strategic direction.
Key Players & Entities
- Cidara Therapeutics, Inc. (company) — Filer of the DEF 14A
- June 18, 2025 (date) — Date of the 2025 annual meeting of stockholders
- December 31, 2024 (date) — Fiscal year end for which compensation is detailed
- K2 Therapeutics, Inc. (company) — Former company name
FAQ
When is the 2025 annual meeting of stockholders for Cidara Therapeutics, Inc.?
The 2025 annual meeting of stockholders for Cidara Therapeutics, Inc. is scheduled for June 18, 2025.
What is the fiscal year end reported in this DEF 14A filing?
The fiscal year end reported in this DEF 14A filing is December 31, 2024.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, a Definitive Proxy Statement, is used to solicit proxies from shareholders regarding matters to be voted on at a shareholder meeting.
What are some key topics typically covered in a Cidara Therapeutics DEF 14A filing?
Key topics typically covered include executive compensation, board nominations, and ratification of the independent registered public accounting firm.
What was Cidara Therapeutics, Inc.'s former company name?
Cidara Therapeutics, Inc.'s former company name was K2 Therapeutics, Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Cidara Therapeutics, Inc..